Autoimmunity in vitiligo: Therapeutic implications and opportunities

Therapeutic potential of adipose tissue‐derivatives in modern dermatology

“…179 The antifibrotic effect of the adipose tissue is attributed to the anti-inflammatory properties of the ADSCs. 176,179 1.1.5 | Vitiligo Vitiligo is the most common hypopigmentary disorder characterized by the selective loss of melanocytes in the skin and/or hair with a serious psychosocial impact [180][181][182] Several plausible mechanisms have been proposed to explain melanocyte loss including genetic susceptibility, 183 autoimmunity, 184,185 oxidative stress, autocytotoxic/metabolic mechanism, [186][187][188] impaired melanocyte proliferation migration and/or adhesion 189,190 and premature cell senescence. 191,192 None of these individually fully explain the melanocyte destruction, and an integrated mechanism involving all these processes may be responsible for the depigmented lesions observed in vitiligo.…”

“…Vitiligo is the most common hypopigmentary disorder characterized by the selective loss of melanocytes in the skin and/or hair with a serious psychosocial impact 180–182 Several plausible mechanisms have been proposed to explain melanocyte loss including genetic susceptibility, 183 autoimmunity, 184,185 oxidative stress, autocytotoxic/metabolic mechanism, 186–188 impaired melanocyte proliferation migration and/or adhesion 189,190 and premature cell senescence 191,192 193 .…”

The mosaic of autoimmunity – Finally discussing in person. The 13th international congress on autoimmunity 2022 (AUTO13) Athens

“…The quality of life has been further lowered by its autoimmune character, which leads to chronicity, inconsistent responses to therapy modalities, and recurrent recurrences. Therefore, the goal of treatment should focus on prolonging remission time, preventing recurrences, providing pleasing aesthetic results, and assuring patient satisfaction [ 43 ]. The primary methods to largely accomplish the specified objectives are promoting melanogenesis and inhibiting cytokine signaling through targeted immunotherapy using corticosteroids and other immunosuppressants.…”

Arrest of progression and duration to achieve it: an important indicator for efficacy of medication aimed at rapidly progressive vitiligo

“…Another point that we want to emphasize is that OMP was particularly introduced for rapidly progressive disease, thus using it in static or slowly progressive vitiligo might not show its full potential. Similarly, its role in segmental vitiligo is obviously not there, because the mechanism is different, 7 so we also humbly disagree with the following points made in the systematic review: aThe comment on the risk of bias, at least in one study. bThe lack of diversity due to all four studies included from India does not mean much because a large number of vitiligo‐related literature emanates from India, as vitiligo has a more psychosocial impact on Indian skin compared with various Caucasian groups the world over. One study from Austria by Radakovic‐Fijan et al 8 .…”